Vulvar Cancer Global Market Report 2025

The vulvar cancer market size has grown strongly in recent years. It will grow from $0.57 billion in 2024 to $0.62 billion in 2025 at a compound annual growth rate (CAGR) of 9.7%. The growth in the historic period can be attributed to the rising adoption of immunotherapy, an increasing incidence of vulvar cancer, greater investments in research and development, expanding government initiatives, and the growing use of HPV vaccines.

The vulvar cancer market size is expected to see strong growth in the next few years. It will grow to $0.89 billion in 2029 at a compound annual growth rate (CAGR) of 9.3%. The growth in the forecast period can be attributed to the increasing demand for therapeutic options, the rising adoption of targeted therapies, a greater focus on early cancer diagnosis, an emphasis on personalized medicine, and the expansion of screening programs. Key trends during this period include advancements in targeted and combination therapies, the growing role of personalized medicine, strategic collaborations, and the adoption of robotic-assisted surgery.

The increasing investments in oncology research and medicine are expected to drive the growth of the vulvar cancer market in the coming years. These investments, made by governments, pharmaceutical companies, research institutions, and private investors, aim to advance the understanding, prevention, diagnosis, and treatment of cancer. The rising global cancer burden, advancements in precision medicine, demand for innovative therapies, expanding clinical trials, government and private funding initiatives, and the development of targeted and immunotherapy treatments contribute to this surge in investments. These financial contributions support vulvar cancer research by improving early diagnosis, enhancing treatment options such as targeted therapies and immunotherapy, funding clinical trials for more effective drugs, strengthening pediatric cancer care infrastructure, and fostering innovative research to understand the disease’s biology and progression. For example, in May 2024, IQVIA, an India-based information technology company specializing in advanced analytics, reported that global spending on cancer medicine increased to $223 billion in 2023, reflecting a $25 billion rise from 2022, and is projected to reach $409 billion by 2028. As a result, increasing investments in oncology research and medicine continue to drive the vulvar cancer market.

The growing emphasis on personalized medicine is also expected to contribute to the expansion of the vulvar cancer market. Personalized medicine involves tailoring medical treatments to individual patients based on genetic, environmental, and lifestyle factors. This approach is gaining traction as it enhances treatment effectiveness and minimizes adverse effects by addressing patient-specific differences. In the case of vulvar cancer, personalized medicine helps optimize treatments based on a patient’s genetic profile, leading to improved outcomes and reduced side effects. For example, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that the FDA approved 16 novel personalized therapies for patients with rare diseases in 2023, up from six in 2022. The increasing focus on personalized medicine is, therefore, contributing to the growth of the vulvar cancer market.

Leading companies in the vulvar cancer market are prioritizing innovations in cancer therapy, including advancements in alpha-radiation cancer therapy, to improve treatment efficacy and patient outcomes. Alpha-radiation cancer therapy involves the targeted delivery of alpha particles to tumor cells, causing localized damage to cancerous tissue while minimizing harm to surrounding healthy cells. For instance, in May 2023, Alpha Tau Medical Ltd., an Israel-based company, announced the first use of its Alpha DaRT alpha-radiation cancer therapy to treat squamous cell carcinoma of the vulva. The study, conducted at Addenbrooke's Hospital within the Cambridge University Hospitals NHS Foundation Trust, aims to recruit 10 participants to evaluate the therapy’s safety and effectiveness. Alpha DaRT offers a targeted, minimally invasive treatment approach, highlighting its potential as a non-surgical option for vulvar cancer.

Major players in the vulvar cancer market are F. Hoffmann-La Roche Ltd, Merck and Co., Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Amgen Inc., Siemens Healthineers, Teva Pharmaceutical, Regeneron Pharmaceuticals, Inc., Intuitive Surgical Operations Inc., Sun Pharmaceuticals Ltd., Genentech Inc, Varian Medical Systems Inc., Ono Pharmaceuticals Co. Ltd., Elekta AB, Accuray Incorporated., Xencor, Nordion Inc., ISA Pharmaceuticals BV, Alpha Tau Medical Ltd.

North America was the largest region in the vulvar cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in vulvar cancer report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the vulvar cancer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Vulvar cancer is a type of cancer that develops in the vulva, the external part of the female genitalia. It usually originates in the skin or tissues of the vulva and may affect the labia, clitoris, or vaginal opening. The most common type is squamous cell carcinoma, which is often associated with human papillomavirus (HPV) infection. Symptoms can include itching, pain, and visible growths or sores on the vulva.

The main types of vulvar cancer include vulvar squamous cell carcinoma (SCC), vulvar melanoma, adenocarcinoma, and basal cell carcinoma. Vulvar SCC originates in the squamous cells of the vulva and is the most prevalent form. Treatment options include chemotherapy, surgery, laser surgery, excision, skinning vulvectomy, radical vulvectomy, radiation therapy, and biologic therapy. These treatments are distributed through online and offline channels and are utilized by various end users, including hospitals and clinics, research and academic institutes, and other healthcare facilities.

The vulvar cancer market research report is one of a series of new reports that provides vulvar cancer market statistics, including vulvar cancer industry global market size, regional shares, competitors with a vulvar cancer market share, detailed vulvar cancer market segments, market trends and opportunities, and any further data you may need to thrive in the vulvar cancer industry. This vulvar cancer market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The vulvar cancer market consists of revenues earned by entities by providing services such as diagnostic testing, clinical consultations, immunotherapy, targeted therapy, and post-treatment care and monitoring. The market value includes the value of related goods sold by the service provider or included within the service offering. The vulvar cancer market also includes sales of pharmaceuticals, immunotherapy drugs, targeted therapy medications, diagnostic kits, and medical devices for tumor detection and monitoring. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.